ArticleOncology letters2026
Androgen receptor drives lenvatinib resistance in hepatocellular carcinoma through transcriptional activation of EIF3I and a downstream ceRNA axis.
Article in Oncology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lenvatinib resistance is a notable clinical challenge in advanced hepatocellular carcinoma (HCC). Androgen receptor (AR) upregulation has been associated with poor prognosis and high invasiveness, particularly in AR-high HCC, yet its specific role in lenvatinib resistance remains unclear. The present study investigated whether AR confers resistance through regulating the circular RNA hsa_circ_0011385. Bioinformatic screening and experimental validation identified hsa_circ_0011385 as significantly upregulated in HCC tissues and AR-high cell lines. In established lenvatinib-resistant cells (MHCC97H-LR), AR, hsa_circ_0011385 and Akt3 were upregulated, while miR-212-5p was downregulated. Mechanistically, AR directly bound to the promoter of eukaryotic translation initiation factor 3 subunit I (EIF3I), the host gene of hsa_circ_0011385 and promoted its transcription. The upregulated hsa_circ_0011385 acted as a molecular sponge for miR-212-5p, thereby relieving its inhibition of the downstream oncogene Akt3. Functional assays showed that AR knockdown sensitized resistant cells to lenvatinib, inhibiting proliferation and migration while promoting apoptosis, whereas overexpressing hsa_circ_0011385 reversed these effects. To the best of our knowledge, the present study revealed for the first time that in AR-high HCC, AR drives lenvatinib resistance by activating the EIF3I/hsa_circ_0011385/miR-212-5p/Akt3 axis. This finding provides a new theoretical basis and potential therapeutic targets for overcoming lenvatinib resistance in this patient subset.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.